Raymond Parker is special counsel in Cooley's Intellectual Property group and is a member of the Patent Counseling & Prosecution practice group. He joined the firm in 2014 and is resident in the New York office.
Dr. Parker has over 25 years of experience building and safeguarding commercially significant IP positions in the pharmaceutical space, having held senior in-house legal positions at some of the largest pharmaceutical companies in the world such as Johnson & Johnson, Eli Lilly, and Sanofi-Aventis. Most recently, he served as the Assistant General Counsel at Aptalis Pharma where he was responsible for managing and protecting all of the company's intellectual property. He supervised a team of internal and external IP practitioners and engaged with outside counsel to handle Aptalis' global IP litigation, including Paragraph IV litigation, as well as patent and trademark oppositions.
Dr. Parker has substantial experience drafting and prosecuting patent applications, managing trademark portfolios, conducting trademark clearances, managing domain names, undertaking patent opinion analyses, conducting licensing and due diligence assessments, counseling internal and external clients, managing adversarial actions, and managing and training patent practitioners. He has lectured extensively on an assortment of US and foreign intellectual property issues, including patenting of follow-on biological therapeutics and polymorphs, strategic management of intellectual property assets, analyzing and critiquing patent cases before the US Supreme Court such as Paragraph IV strategies, safe harbor provisions of §271(e)(1) in view of Merck v. Integra and obviousness considerations in view of KSR, and discussing the importance of intellectual protection of pharmaceuticals from the R&D stage through the drug approval process.
He has expertise in devising innovative tools and practices for improving the procurement of patents, developing corporate responses to legislative and administrative patent related initiatives, developing strategies for responding to improper Patent Office positions, such as the restricting of Markush claims, patenting of polymorphs and procuring a proprietary position for reformulated drugs, and enhancing the defensive and offensive character of patents.
Dr. Parker has authored nearly 50 publications and presentations covering various aspects of intellectual property protection in the pharmaceutical and life sciences sectors.
